Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus β-lactamase-producing Enterobacteriaceae

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 9, 2010, Pages 1972-1974

  Livermore, David M ^a   Mushtaq, Shazad ^a   Ge, Yigong ^b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b Calixa Therapeutics Inc ^*  (United States)

Author keywords

AmpC; CXA 201; ESBLs; Synergy; lactamase inhibitors

Indexed keywords

BACTERIAL ENZYME; BETA LACTAMASE AMPC; BETA LACTAMASE K1; BETA LACTAMASE KPC; CARBAPENEMASE; CEPHALOSPORIN DERIVATIVE; CXA 101; EXTENDED SPECTRUM BETA LACTAMASE; FR 264205; TAZOBACTAM; UNCLASSIFIED DRUG;

AGAR DILUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CITROBACTER FREUNDII; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENTEROBACTER; ENTEROBACTERIACEAE; ESCHERICHIA COLI; KLEBSIELLA OXYTOCA; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; NONHUMAN; REDUCTION; SERRATIA MARCESCENS; STRAIN DIFFERENCE; TITRIMETRY;

EID: 77955618992     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq248     Document Type: Article

References (14)

1. Livermore DM, Mushtaq S, Ge Y et al. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. Int J Antimicrob Agents 2009; 34: 402-6.
2. Mushtaq S, Warner M, Livermore DM et al. Activity of cephalosporin CXA-101 (FR264205) with β-lactamase inhibitors vs. Enterobacteriaceae. In: Abstracts of the Forty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America Forty-sixth Annual Meeting, Washington, DC, 2009. Abstract F1-356, p. 284. American Society for Microbiology, Washington, DC, USA.
3. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Testing of Bacteria That Grow Aerobically-Seventh Edition: Approved Standard M7-A7. CLSI, Wayne, PA, USA, 2009.
4. Livermore DM, Yuan M. Antibiotic resistance and production of extended-spectrum β-lactamases amongst Klebsiella spp. from intensive care units in Europe. J Antimicrob Chemother 1996; 38: 409-24.
5. Babini GS, Livermore DM. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. J Antimicrob Chemother 2000; 45: 183-9.
6. Potz NA, Hope R, Warner M et al. Prevalence and mechanisms of cephalosporin resistance in Enterobacteriaceae in London and South-East England. J Antimicrob Chemother 2006; 58: 320-6.
7. Bush K, Macalintal C, Rasmussen BA et al. Kinetic interactions of tazobactam with β-lactamases from all major structural classes. Antimicrob Agents Chemother 1993; 37: 851-8.
8. Livermore DM. β-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-84.
9. Canton R, Coque TM. The CTX-M β-lactamase pandemic. Curr Opin Microbiol 2006; 9: 466-75.
10. Livermore DM, Canton R, Gniadkowski M et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007; 59: 165-74.
11. Babini GS, Yuan M, Hall LM et al. Variable susceptibility to piperacillin/tazobactam amongst Klebsiella spp. with extended-spectrum β-lactamases. J Antimicrob Chemother 2003; 51: 605-12.
12. Akova M, Yang Y, Livermore DM. Interactions of tazobactam and clavulanate with inducibly-and constitutively-expressed class I β-lactamases. J Antimicrob Chemother 1990; 25: 199-208.
13. Takeda S, Ishii Y, Hatano K et al. Stability of FR264205 against AmpC β-lactamase of Pseudomonas aeruginosa. Int J Antimicrob Agents 2007; 30: 443-5.
14. Fournier B, Lagrange PH, Philippon A. In-vitro susceptibility of Klebsiella oxytoca strains to 13 β-lactams in the presence and absence of β-lactamase inhibitors. J Antimicrob Chemother 1996; 37: 931-42.